Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital
Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price reduced by Chardan Capital from $11.00 to $7.00 in a research note issued to investors on Monday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock. A number of other equities research analysts also recently issued reports on IPSC. Piper Sandler lowered […]
Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price reduced by Chardan Capital from $11.00 to $7.00 in a research note issued to investors on Monday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock. A number of other equities research analysts also recently issued reports on IPSC. Piper Sandler lowered […]
